Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mach7 TechnologiesASX:M7T -6.25%26 Return-on-Tangible-Asset is -30.15% as of Dec. 2025. GuruFocus rates ASX:M7T with a GF Score™ of 26/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Mach7 Technologies ranks worse than 80.67% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mach7 Technologies's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-11.50 Mil. Mach7 Technologies's average total tangible assets for the quarter that ended in Dec. 2025 was A$38.13 Mil. Therefore, Mach7 Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -30.15%.
The historical rank and industry rank for Mach7 Technologies's Return-on-Tangible-Asset or its related term are showing as below:
ASX:M7T'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -316.9 Med: -19.72 Max: 0.54
Current: -24.58
During the past 13 years, Mach7 Technologies's highest Return-on-Tangible-Asset was 0.54%. The lowest was -316.90%. And the median was -19.72%.
ASX:M7T's Return-on-Tangible-Asset is ranked worse than 80.67% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs ASX:M7T: -24.58
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mach7 Technologies Return-on-Tangible-Asset Related Terms
Mach7 Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Mach7 Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:M7T vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Mach7 Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mach7 Technologies Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mach7 Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -30.15% mean?
Mach7 Technologies (ASX:M7T) has a Return-on-Tangible-Asset of -30.15% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #551 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 80.7%.
Is Mach7 Technologies' Return-on-Tangible-Asset too high?
Mach7 Technologies' current Return-on-Tangible-Asset is -30.15%. Based on the distribution chart, Mach7 Technologies ranks #551 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mach7 Technologies has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #551 out of 683 companies for Return-on-Tangible-Asset. This places Mach7 Technologies in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mach7 Technologies and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mach7 Technologies's current Return-on-Tangible-Asset is -30.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (ASX:M7T) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.30 — trading 64.3% below its estimated fair value. The current Return-on-Tangible-Asset is -30.15%. Mach7 Technologies' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mach7 Technologies (ASX:M7T), the current Return-on-Tangible-Asset is -30.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mach7 Technologies (ASX:M7T) Overvalued in 2026?
Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued.
The current stock price of A$0.30 is trading 64.3% below its estimated GF Value™ of A$0.84.
GuruFocus considers Mach7 Technologies to be Possible Value Trap.
Key valuation signals for ASX:M7T:
Return-on-Tangible-Asset: -30.15%
GF Value™: A$0.84 vs. price of A$0.30 (64.3% below fair value)
No single metric tells the full story. See the ASX:M7T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
26GF Score
Get the complete analysis for ASX:M7T
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:M7T has been successfully added to your 
